San
Francisco, Dec 04 The global structural
heart devices market is expected to reach USD 9.1 billion by 2025,
based on a new report by Grand View Research, Inc. The market is expected to
witness an exponential growth over the next 8 years due to the rapid increase
in cardiovascular conditions and increasing power of healthcare expenditure.
The defects are mostly present
at birth, thereby directly affecting the under-5 mortality rate of a country.
Therefore, rigorous actions are being undertaken by various government bodies
across the globe to increase access to treatment. The Centers for Disease
Control and Prevention have a public action plan to efficient management of
cardiac conditions.
In addition, other
organizations are working on improving the scenario for structural heart
diseases treatment. For instance, in November 2016, the Cardiovascular Research
Foundation (CRF) announced a launch of a journal focusing on diagnosis and
treatment of structural heart defects. It was titled Structural Heart:
The Journal of the Heart Teamand is expected to be launched in May 2017.
This is expected to trigger research & development activities along with
capital invested in this field, resulting in technological advancements.
Browse full research report on Structural Heart Devices Market:
www.grandviewresearch.com/industry-analysis/structural-heart-devices-market
Further key
findings from the study suggest:
- Surgical Aortic Valve Replacement (SAVR)
dominated the market in 2016, closely followed by Transcatheter Aortic
Valve Replacement (TAVR). It can be attributed to the longest presence of
the technique in the treatment regimen of aortic stenosis
- Left Atrial Appendage Closure (LAAC) is
anticipated to be one of the fastest growing segment owing to the
minimally invasive nature of the procedure. It also helps in reduction of
risk of stroke, thus is projected to have a higher demand
- Geographically, North America held the largest
market share in 2016 and is expected to maintain its position during the
forecast period. High prevalence of cognitive heart diseases is the key
reason for this dominance. Moreover, the mandatory CCHD screening for
newborns imposed by the Centers for Disease Control and Prevention (CDC)
and American Academy of Pediatrics (AAP) in September 2014 also
contributes to the growth in this region
- Asia Pacific is also expected to witness a rapid
growth over the forecast period. The improved access and capability for
treatments in this region is the key reason for this growth
- Some of the key players are Medtronic, ST. JUDE
MEDICAL, Boston Scientific Corporation, CardioKinetix, Comed BV, Edwards
Lifesciences Corporation, LivaNova PLC, Abbott Laboratories, JenaValve
Technology, Inc., and Biomerics
Browse more reports of this category
by Grand View Research: www.grandviewresearch.com/industry/healthcare
Grand View Research has
segmented the structural heart devices market by type and region:
Type Outlook
(Market Revenue in USD Million, 2014 - 2025)
- SAVR
- TAVR
- Mitral Repair (Annuloplasty)
- LAAC
Regional Outlook (Market
Revenue in USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Mexico
- Middle East and Africa
- South Africa
Browse press release of this report
by Grand View Research: www.grandviewresearch.com/press-release/global-structural-heart-devices-market
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information:
www.grandviewresearch.com
No comments:
Post a Comment